

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

REMARKS

Claims 12, 14, 17, 19, 29, and 36-41 are pending. Claims 12, 14, 19, and 36-41 have been amended herein; the amendments do not introduce any new matter to the pending claims.

Rejection of Claims 36 and 37 Under 35 U.S.C. § 112, Second Paragraph

Claims 36 and 37 stand rejected under 35 U.S.C. § 112, second paragraph, as indefinite. According to the Examiner, the indefiniteness is due to insufficient antecedent basis for the term “non-metastatic control” in claim 36 and its dependent claim 37.

Claim 36 as amended no longer recites “non-metastatic control,” and the amended term “metastatic control” has antecedent basis. Additionally, Applicants have amended claim 37, as well as claims 19, 39, and 41, to recite “human” instead of “mammal.”

Accordingly, Applicants respectfully request reconsideration and withdrawal of this rejection.

Rejection of Claims 12, 17, 19, 36, and 37 Under 35 U.S.C. § 112, First Paragraph

Claims 12, 17, 19, 36, and 37 stand rejected under 35 U.S.C. § 112, first paragraph, as failing to meet the written description requirement, because the limitation of “excluding RhoC” allegedly represents new matter. According to the Examiner, this exclusion proviso represents new matter based on Ex parte Grasselli, 231 U.S.P.Q. 393 (Bd. App. 1983), which holds that “mere absence of a positive recitation is not basis for an exclusion.” MPEP 2173.05(i).

However, the instant situation does not present a case of “mere absence of a positive recitation,” because RhoC is positively recited throughout the application, along with other proteins, such as proteins associated with the actin-based cytoskeleton (e.g., page 9, lines 5-20 of the specification as filed) or the proteins listed in Table 5 as filed. MPEP 2173.05(i) also states: “If alternative elements are positively recited in the specification, they may be explicitly excluded in the claims. See In re Johnson, 558 F.2d 1008, 1019, 194 USPQ 187, 196 (CCPA 1977) (“[the] specification, having described the whole, necessarily described the part

Rejection of Claims 12, 14, 17, 19, 29, 36-41 Under 35 U.S.C. § 112, First Paragraph

Claims 12, 14, 17, 19, 29, 36-41 stand rejected under 35 U.S.C. § 112, first paragraph for lack of enablement. The Examiner has reiterated that the claims as written are extremely broad because the exact nature of the likelihood of development of metastasis; the stage of the mammal's life the development occurs; the extent of species metastasis covered; the development of metastasis from a neoplasm of any tissue in a human; the range of biological samples that can be used in testing; and nature of alteration of the cytoskeleton causing metastasis are not described in such a way as to enable one of skill in the art to make and/or use the invention.

The claims as amended recite a method of predicting the likelihood of developing a metastatic condition in a human, wherein if the level of one or more gene products in a sample as determined in step (a) of the claim is greater than the level of gene product in the non-metastatic control there is an increased likelihood of developing a metastatic condition, or alternatively, wherein the level of one or more gene products in a sample as determined in step (a) of the claim is the same as the level of gene product in the metastatic control there is an increased likelihood of developing a metastatic condition.

The Examiner has cited various prior art to show the state of the prior art and level of predictability in the art. Specifically, the Examiner has cited multiple references that show seemingly contradictory results with respect to the correlation of the expression level of fibronectin with metastasis. However, all of the references (Christensen *et al.*, [Guo] Linlang *et al.*, Takei *et al.*, and Xu *et al.*, as well as previously cited Fleischmann *et al.*) employ immunohistochemical or immunostaining methodology to determine the level of fibronectin expression in various lesion or tumor samples. The specificity and sensitivity of the immunostaining methodology are hardly comparable to the array technology employed in the examples of the instant invention which can detect mRNAs at much higher sensitivity and specificity (e.g., page 30, lines 5-10 of the specification). Therefore, while the state of the prior art is unclear, Applicants' examples are based on more advanced, reliable technology and clearly demonstrate that increased expression of fibronectin is in fact detected in metastases and correlates with an increased likelihood of developing a metastatic condition.

demonstrate that increased expression of fibronectin is in fact detected in metastases and correlates with an increased likelihood of developing a metastatic condition.

The Examiner has commented on the existence of working examples, stating that the instant invention does not teach how to obtain a biological sample as recited in the claims at issue. Based on the references the Examiner has cited with regard to fibronectin expression, Applicants submit that biological samples such as autopsy samples as used in Christensen *et al.* (which may be a metastatic control), breast cancer specimens as used in Takei *et al.*, serum and laryngeal normal and cancer tissues as used in Xu *et al.*, liver as used in [Guo] Linlang *et al.*, can be obtained by well-known methods in the art.

The Examiner has also raised the issue of working examples. In response to Applicants' remarks filed in the previous Amendment, the Examiner also cites van Gronigen *et al.* (Cancer Research, 55: 6237-43 (1995)), the primary reference cited for an obviousness rejection as discussed in greater detail below. The Examiner states that "the teachings of van [sic] Gronigen *et al.* provide at least as much as the examples in the specification (with regard to the fact that both show differential expression in tumor cell lines of varying metastatic potential)." Applicants respectfully traverse this characterization of the instant invention. In contrast to van Gronigen's limited teachings on differential expression in tumor cell lines, the instant invention provides ample examples of gene products with enhanced expression in metastases, not cell lines in culture (e.g., page 30, lines 20-24 of the specification). The metastases are lesions obtained from a murine metastasis model, and murine models for studying metastasis are well accepted by skilled artisans. See, e.g., An *et al.*, Anticancer Res. 16:627-31 (1996) and Clin. Exp. Metastasis 15:184-95 (1997) (Exhibit A); Cher, 5R01CA088028-03 (Exhibit B) and Anderson, 5R01CA090291-02 (Exhibit C), Grant Abstracts, National Cancer Institute. Further, experimental findings that support the instant invention have also been published by the highly acclaimed, peer-review scientific journal Nature (Clark *et al.*, Nature, 406: 532-35 (August 2000)) (Exhibit D).

Applicants maintain that the instant invention is an assay for analyzing the expression levels of one or more gene products which Applicants have discovered to be statistically significant markers for predicting the likelihood of the development of a metastatic condition. As the Examiner has pointed out through Steeg *et al.* (U.S. Patent No. 5,049,662), a secondary reference cited in the rejection under 35 U.S.C. § 103(a) (see below), as well as other references

discussed above, one of skill in the art would be able to obtain a sample, determine the level of expression of a gene product in the sample, and compare the expression level of a gene product in a sample to the level of expression of a gene product in a control without undue experimentation. The present invention teaches that by looking at the expression levels of specific gene products, e.g., genes which control the actin-based cytoskeleton, wherein if the level of one or more gene products is greater than the level of the gene product(s) in a non-metastatic control, or alternatively, wherein if the level of one or more gene products is the same as the level of the gene product(s) in a metastatic control, there is an increased likelihood of the development of a metastatic condition.

To reiterate, Applicants provide ample teachings throughout the specification wherein the level of one or more identified gene products, e.g., gene products that alter the actin-based cytoskeleton, has been shown to be higher in individuals with a metastatic condition than non-metastatic condition. Applicants have examined one stage of neoplasm progression (the development of metastases) and teach that there is an identifiable difference between neoplasms that metastasize and neoplasms that do not. As such, Applicants teach a correlation between the increased expression of gene products that alter the actin-based cytoskeleton with an increased likelihood of developing a metastatic condition. Thus, Applicants have demonstrated a role for cytoskeletal organization/re-organization in tumor metastasis.

Accordingly, Applicants claim a method and teach what the components of the method are, how the components are measured, and what the result of the method means. Applicants maintain that the specification and the pending claims enable one of skill in the art to practice the invention as currently claimed without undue experimentation. Reconsideration and withdrawal of the rejection are respectfully requested.

Rejection of Claims 12, 17, 19, 36, and 37 Under 35 U.S.C. §103(a)

Claims 12, 17, 19, 36, and 37 are rejected under 35 U.S.C. §103(a) as being unpatentable over van Gronigen *et al.* (Cancer Research, 55: 6237-43 (1995)) (“van Gronigen”) in view of Steeg *et al.* (U.S. Patent No. 5049662) (“Steeg”).

According to the Examiner, it would have been obvious to one of ordinary skill in the art at the time the application was filed to modify the assay of van Gronigen in order to form a

diagnostic assay as taught by Steeg because of the demonstrated correlation between elevated gene expression and metastatic potential.

Claims 12 and 36 are independent method claims comprising a step of determining the level of one or more gene products, excluding RhoC, which alter the actin-based cytoskeleton of one or more tumor cells in the human. Claims 17 and 19 are dependent on Claim 12, and Claim 37 depends from Claim 36. As discussed above, the instant invention provides multiple examples of gene products that alter the actin-based cytoskeleton and are determined to have significantly enhanced expression in melanoma metastases using a well-established, widely used murine model, not cell lines in culture (page 31, lines 15-25 of the specification).

In contrast, van Gronigen teaches differential mRNA display in human melanoma cell lines in culture with different metastatic capacities. By comparing levels of mRNAs from highly metastatic human melanoma cell lines with poorly metastatic human melanoma cells lines, van Gronigen has identified 9 mRNAs that are differentially expressed in the cell lines of different metastatic capacities, one of which being 98% homologous to a human mRNA fragment of laminin B2. Fig 2. of van Gronigen represents the only teaching that laminin B2 mRNA is detected in a highly metastatic cell line in culture (page 6239). Van Gronigen does not teach determining laminin B2 mRNA level in melanoma metastasis lesions. The only gene product that van Gronigen has determined to be expressed in melanoma lesions is melanoma inhibitory activity ("MIA"), which contradicts van Gronigen's own finding that MIA is only detectable in poorly metastasizing cell lines in culture (page 6241, column 2, second paragraph). Therefore, van Gronigen does not teach enhanced laminin B2 expression in melanoma metastases, which, according to van Gronigen, represent different cell growth stages and may present a contradictory result, similar to MIA. That is, there is no reasonable expectation of success provided by van Gronigen in using laminin B2 to predict the likelihood of developing a metastatic condition in a human, because expression data from van Gronigen's cell line experiments may not correlate with expression levels in metastasis lesions.

Steeg does not provide the teaching or suggestion which van Gronigen lacks. To reiterate, Steeg describes the identification of the NM23 gene and its use for predicting metastatic potential in animal experimental model systems and human cancer. Steeg goes on to describe that NM23 RNA levels were greatest in cells and tumors of low metastatic potential, and declined in highly metastatic specimens. Steeg does not disclose any genes other than

NM23, correlate any genes other than NM23 with metastasis or teach that any gene other than NM23 could be used to predict the likelihood of developing a metastatic condition. Moreover, there is no teaching in Steeg that NM23 is involved with the actin-based cytoskeleton.

The cited references, alone or in combination, do not teach or suggest the methods of the instant claims, as amended. As such, the claimed invention is not obvious over the prior art. Accordingly, reconsideration and withdrawal of the rejection are respectfully requested.

CONCLUSION

In view of the above, each of the presently pending claims in this application is believed to be in immediate condition for allowance. Accordingly, the Examiner is respectfully requested to pass this application to issue. . If the Examiner feels that a telephone conference would expedite prosecution of this case, the Examiner is invited to call the undersigned at (617) 951-7000.


A Petition for a three-month extension of time and appropriate fee are filed concurrently herewith. If an additional fee is due, please charge our Deposit Account No. 18-1945, under Order No. WIBL-P01-534 from which the undersigned is authorized to draw.

Dated: May 7, 2004

Respectfully submitted,

By Lisa M. Treannie
Lisa Treannie

Registration No.: 41,368
ROPES & GRAY LLP
(Customer No: 28120)
One International Place
Boston, Massachusetts 02110-2624
(617) 951-7000
(617) 951-7050 (Fax)
Attorneys/Agents For Applicant



Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals

Search PubMed for Go Clear

Limits Preview/Index History Clipboard Details

About Entrez

Display Abstract Show: 20 Sort Send to Text

Text Version

☐ 1: Anticancer Res. 1996 Mar-Apr;16(2):627-31.

Related Articles, Link

Entrez PubMed

Overview
Help | FAQ
Tutorial
New/Noteworthy
E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
Cubby

Related Resources
Order Documents
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

Privacy Policy

A clinical nude mouse metastatic model for highly malignant human pancreatic cancer.

An Z, Wang X, Kubota T, Moossa AR, Hoffman RM.

AntiCancer Inc., San Diego, CA 92111, USA.


Pancreatic cancer is a highly aggressive and treatment-refractory cancer. A clinically-relevant animal model is necessary to develop therapy for metastatic pancreatic cancer. In this study we evaluated the efficacy of mitomycin C (MMC) and 5-FU against the human pancreatic adenocarcinoma cell line PAN-12 in an orthotopic human metastatic pancreatic cancer nude mice model. The model is constructed by surgical orthotopic implantation (SOI) of histologically intact tumor tissue in the tail portion of the pancreas near the spleen. PAN-12 grew very aggressively in the control group of nude mice with extensive local invasion and distant metastasis to various organs with a propensity for the lung but to other organs as well, including the liver, kidney and regional and distant lymph nodes. In a striking effect none of the mice in the MMC-treated group developed tumor. Although mice in the 5-FU treated group survived statistically significantly longer than those in the untreated control, the overall incidence of metastasis in these mice was equivalent to those in the control. However no liver or kidney metastases were found in the 5-FU treated animals perhaps accounting in part for their longer survival. This "clinical" nude mouse model of highly metastatic pancreatic cancer can now be used to discover new effective agents for this disease.

PMID: 8687107 [PubMed]

Display Abstract Show: 20 Sort Send to Text

[Write to the Help Desk](#)[NCBI](#) | [NLM](#) | [NIH](#)[Department of Health & Human Services](#)[Freedom of Information Act](#) | [Disclaimer](#)

May 3 2004 06:56:



Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Br

Search PubMed for Go Clear

Limits Preview/Index History Clipboard Details

About Entrez

Display Abstract Show: 20 Sort Send to Text

Text Version

☐ 1: Clin Exp Metastasis. 1997 Mar;15(2):184-95.

Related Articles, Lin

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

Related Resources

Order Documents

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

Privacy Policy

Conversion of highly malignant colon cancer from an aggressive to a controlled disease by oral administration of a metalloproteinase inhibitor.**An Z, Wang X, Willmott N, Chander SK, Tickle S, Docherty AJ, Mountain A, Millican AT, Morphy R, Porter JR, Epemolu RO, Kubota T, Moossa AR, Hoffman RM.**

AntiCancer Inc., San Diego, CA, USA.

In this study, we describe the activity of CT1746, an orally-active synthetic MMP inhibitor that has a greater specificity for gelatinase A, gelatinase B and stromelysin than for interstitial collagenase and matrilysin, in a nude mouse model that better mimics the clinical development of human colon cancer. The model is constructed by surgical orthotopic implantation (SOI) of histologically-intact tissue of the metastatic human colon tumor cell line Co-3. Animals were gavaged with CT1746 twice a day at 100 mg/kg for 5 days after the SOI of Co-3 for 43 days. In this model CT1746 significantly prolonged the median survival time of the tumor-bearing animals from 51 to 78 days. Significant efficacy of CT1746 was observed on primary tumor growth (32% reduction in mean tumor area at day 36), total spread and metastasis (6/20 treated animals had no detectable spread and metastasis at autopsy compared to 100% incidence of secondaries in control groups). Efficacy of CT1746 could also be seen on reducing tumor spread and metastasis to individual organ sites such as the abdominal wall, cecum and lymph nodes compared to vehicle and untreated controls. We conclude that chronic administration of a peptidomimetic MMP inhibitor via the oral route is feasible and results in inhibition of solid tumor growth, spread and metastasis with increase in survival in this model of human cancer, thus converting aggressive cancer to a more controlled indolent disease.

PMID: 9062395 [PubMed]

Display Abstract Show: 20 Sort Send to Text

[Write to the Help Desk](#)
[NCBI](#) | [NLM](#) | [NIH](#)
[Department of Health & Human Services](#)
[Freedom of Information Act](#) | [Disclaimer](#)

May 3 2004 06:56:



Division of
Cancer Biology

[Home](#)[OD](#)[CCBB](#)[CEB](#)[CIHB](#)[DCAB](#)[SBMAB](#)[TBMB](#)**Abstract****5R01CA088028-03****Cher, Michael L****WAYNE STATE UNIVERSITY****PROSTATE CANCER, BONE METASTASIS, AND
METALLOPROTEINASES**

DESCRIPTION: (Adapted from the investigator's abstract) Metastasis of prostate cancer to bone causes increased turnover of bone matrix and is frequently accompanied by pain and pathological fractures. Radiologically, prostate cancer metastases are "blastic," however, on a biochemical level, they are both lytic and blastic. The cellular and biochemical mechanisms underlying the enhanced turnover of bone matrix associated with metastatic cancer are unknown. The "SCID-human model of prostate cancer metastasis to bone," recently developed in our laboratory, mimics clinical disease on several levels: prostate cancer cells home to human bone implanted in SCID mice, they grow more rapidly in bone as compared to other tissue environments, and there is rapid turnover of bone matrix. In this and other models, we found that prostate cancer cells growing in bone produce and/or secrete matrix metalloproteinases (MMPs) including MMP-2, MMP-9 and MT1-MMP. These proteinases are enzymatically competent to degrade bone matrix, and they normally participate in several of the steps of bone matrix metabolism. For example, osteoblasts use MMPs to digest nonmineralized bone matrix, and this leads to recruitment of osteoclasts and enhanced osteoclastic degradation of mineralized matrix. We hypothesize that prostate cancer cells degrade nonmineralized matrix in a fashion similar to osteoblasts and that production of MMP-2, MMP-9, and MT1-MMP by metastatic prostate cancer cells may contribute to the enhanced bone matrix turnover associated with metastatic disease. Using the in vivo SCID-human system and an in vitro bone organ culture model, we will test the hypothesis that: (1) the bone environment induces an upregulation of MMP-2, MMP-9 and MT1-MMP expression in prostate cancer cells and an increase in MMP-2, MMP-9 secretion and activity; (2) there is MMP activity at the interface between prostate cancer cells and the nonmineralized bone matrix; and (3) MMP production/secretion by prostate cancer cells in the bone environment leads to tumor cell proliferation, and migration of tumor cells to endosteal surfaces; degradation of nonmineralized bone matrix; recruitment of osteoclasts; and enhanced osteoclast activity and degradation of mineralized matrix. These experiments will take advantage of our model systems and a variety of prostate cancer cells that produce a spectrum of response in bone ranging from primarily osteolytic to primarily osteoblastic. The results of these studies may lead to new therapeutic strategies aimed at interrupting the interactions between prostate cancer cells and bone.

[Home](#)[NCI](#)[Help](#) | [Contact Us](#) | [Accessibility](#)

cancer.gov
1-800-4-CANCER



National Institutes of Health (NIH)



FIRSTGov
Your First Click to the U.S. Government



Division of
Cancer Biology

[Home](#)[OD](#)[CCBB](#)[CEB](#)[CIHB](#)[DCAB](#)[SBMAB](#)[TBMB](#)**Abstract****5R01CA090291-02****Anderson, Robin L****PETER MACCALLUM CANCER INSTITUTE****GENES IMPORTANT IN BREAST CANCER METASTASIS**

DESCRIPTION (provided by applicant): Breast cancer is the most common cause of cancer death in western women. The majority of breast cancer deaths are due not to the primary tumor but to metastatic disease. Common sites of metastasis include lymph nodes, lung, liver and bone. For example, approximately two thirds of patients with metastatic disease have bone involvement, resulting in severe pain, pathological fractures, hypercalcemia and spinal cord compression. These complications are a significant clinical problem for which there is no effective treatment. The aim of this project is to identify factors that are involved in the metastasis of breast cancer cells to specific sites with the long term objective of developing new diagnostic markers and specific therapies for metastatic disease. Metastasis is a complex process in which cells migrate from the primary tumor to the blood or lymphatic system and hence to distant sites. Many cellular changes and interactions are required during this process. However, our understanding of the process has been hampered by the lack of suitable animal models. We have a unique murine model of breast cancer metastasis comprising genetically matched tumor cell lines all derived from the one spontaneous tumor, that metastasize to different organs such as lymph nodes, lung, liver and bone. Thus, our model provides a powerful system for defining the genetic events that mediate site specific metastasis. The research plan utilizes genetically matched pairs of tumors (from the mouse model) with different metastatic properties to seek differentially expressed genes by cDNA microarray analysis. Once these genes have been identified, expression in human clinical samples will be measured using tumor array technology. Finally, the role in metastasis of relevant genes will be investigated using genetic manipulation of the appropriate tumor cell lines in the mouse metastasis model and in a human breast cancer model. These studies will provide a significant advance in the search for new targets for therapeutic intervention and better diagnostic markers of metastasis.

[Home](#)[NCI](#)[Help](#) | [Contact Us](#) | [Accessibility](#)

cancer.gov
1-800-4-CANCER



National Institutes of Health (NIH)



FIRSTGov
Your First Click to the U.S. Government

30. Christofori, G. & Semb, H. The role of the cell-adhesion molecule E-cadherin as a tumour-suppressor gene. *Trends Biochem. Sci.* 24, 73–76 (1999).

Acknowledgements

We thank L. Meysaard for critically reading the manuscript and members of the Clevers laboratory for helpful discussions; C. Kenyon for the *mab-5* reporter *mul2*; Q. Ch'ng and C. Kenyon for tips on staining *mul2* animals for β -galactosidase expression; and A. Fire for pPD49.78. This work was supported in part by an NIH grant to M.H. and PIONEER and Program grants from NWO Medische Wetenschappen to H.C.

Correspondence and requests for materials should be addressed to H.K. (e-mail: R.Korswagen@lab.azu.nl).

Genomic analysis of metastasis reveals an essential role for RhoC

Edwin A. Clark^{††}, Todd R. Golub^{‡§}, Eric S. Lander^{‡||} & Richard O. Hynes^{*||}

^{*}Howard Hughes Medical Institute, Centre for Cancer Research, and

^{||}Department of Biology, Massachusetts Institute of Technology;


77 Massachusetts Avenue, Cambridge, Massachusetts 02139, USA

[‡]Whitehead Institute/MIT Centre for Genome Research, 9 Cambridge Centre, Cambridge, Massachusetts 02142, USA

[§]Dana-Farber Cancer Institute, 44 Binney Street, Boston, Massachusetts 02115, USA

The most damaging change during cancer progression is the switch from a locally growing tumour to a metastatic killer. This switch is believed to involve numerous alterations that allow tumour cells to complete the complex series of events needed for metastasis¹. Relatively few genes have been implicated in these events^{2–5}. Here we use an *in vivo* selection scheme to select highly metastatic melanoma cells. By analysing these cells on DNA arrays, we define a pattern of gene expression that correlates with progression to a metastatic phenotype. In particular, we show enhanced expression of several genes involved in extracellular matrix assembly and of a second set of genes that regulate, either directly or indirectly, the actin-based cytoskeleton. One of these, the small GTPase RhoC, enhances metastasis when overexpressed, whereas a dominant-negative Rho inhibits metastasis. Analysis of the phenotype of cells expressing dominant-negative Rho or RhoC indicates that RhoC is important in tumour cell invasion. The genomic approach allows us to identify families of genes involved in a process, not just single genes, and can indicate which molecular and cellular events might be important in complex biological processes such as metastasis.

To provide insight into the pattern of gene expression that allows tumours to metastasize, we compared the gene expression profile of melanoma variants with low or high metastatic potential. As shown in Fig. 1, the system involves the *in vivo* selection of highly metastatic melanoma cells from a population of poorly metastatic tumour cells⁶. When nude mice were injected intravenously with amelanotic human A375P tumour cells, relatively few pulmonary metastases were observed (Fig. 2a). When these rare metastases were dissected free from the lungs and the cells grown in tissue culture, however, the resulting cells showed enhanced metastatic capacity, confirming that highly metastatic cells can be selected from a heterogeneous population of poorly metastatic tumour cells⁷. Furthermore, if successive metastases (designated M1 and M2) were isolated, expanded in tissue culture, and re-introduced into



Analysis
Compare parental tumour cell line (A375P or B16F0) grown subcutaneously with the pulmonary metastases (A375M1, M2, SM or B16F1, F2, F3)

Figure 1 *In vivo* selection scheme. Poorly metastatic melanoma cell lines (human A375P or mouse B16F0) were injected intravenously into the tail veins of host mice and pulmonary metastases were isolated. Either these metastases were minced and grown in tissue culture (to be injected into additional host mice) or RNA was extracted to prepare the labelled cRNA used to hybridize to the oligonucleotide arrays. The procedure to select for highly metastatic tumour cells was repeated two (A375) or three (B16) times. A375SM cells were previously derived in a similar manner¹¹.

host mice as shown in Fig. 1, significantly more pulmonary metastases were observed (Fig. 2b). When mouse B16F0 melanoma cells were subjected to this same *in vivo* selection scheme, highly metastatic pulmonary tumours (designated F1, F2 and F3) were isolated, as previously described for this cell line⁶. When the poorly metastatic A375P or B16F0 and the *in vivo*-selected metastatic A375 or B16 cells were grown as subcutaneous tumours, there was no observable difference in tumour size (see Supplementary Information), indicating that we had selected for a difference in metastatic, but not tumorigenic, properties of the melanomas. These results support the hypothesis that specific gene products can regulate metastasis without altering the growth properties of a tumour⁸. Therefore, we sought to identify metastasis-specific genes using a functional genomics approach.

RNAs extracted from these pulmonary metastases and from the parental A375P and B16F0 lines grown as subcutaneous tumours were used to prepare complementary RNAs (cRNAs), which were hybridized to oligonucleotide microarrays (human: 7,070 genes; mouse: 6,347 genes, with around 50% overlap in the genes represented) to determine the array of differentially expressed genes (Fig. 1). The entire data set is available at our web site at <http://www.genome.wi.mit.edu/MPR> and in Supplementary Information. Table 1 lists those genes expressed at consistently higher levels in pulmonary metastases derived from the A375P line (M1, M2 and SM) and the mouse B16F0 line (F1, F2 and F3). To ensure that the enhanced expression of these genes in the pulmonary metastases was not due solely to the influence of the microenvironment in which the metastatic cells were growing, we also grew metastatic A375SM cells subcutaneously and compared their expression profile with that of subcutaneous A375P tumours. We found that 15 of the 16 genes continued to show enhanced expression when metastatic A375 cells were grown as a subcutaneous tumour (see Supplementary Information), indicating that the expression of these genes is intrinsic to the metastatic cells. Note, however, that the tumour microenvironment may help to regulate the absolute level of gene expression.

As the set of genes represented on the human and mouse arrays partially overlapped, some signals appeared in both species (Table 1). Three genes, fibronectin, RhoC and thymosin β 4, were expressed at higher levels (≥ 2.5 -fold) in all three metastases selected from both the human A375 and mouse B16 cell lines. Enhanced expression of these three genes in the pulmonary metastases was

[†]Present address: Millennium Predictive Medicine, One Kendall Square, Cambridge, Massachusetts 02139, USA.




Figure 2 Pulmonary metastases in lungs of mice injected with tumour cell lines. **a**, A375P cells; **b**, A375M; **c**, A375P-RhoC; **d**, A375M-dnRho. Arrows indicate representative metastatic nodules. Scale bar, 1 mm.

confirmed by RNase protection (see Supplementary Information). Note that this assay will detect only human RNAs (from the tumour cells) and not mouse RNAs from stromal or vascular cells. This confirms that changes in expression of these three genes occur in the tumour cells rather than in host tissue. This is also probably true for all the oligonucleotide array data given the sequence divergence between species (Table 1).

Fibronectin is an extracellular glycoprotein that serves as a ligand for the integrin family of cell adhesion receptors and regulates cytoskeletal organization. Fibronectin expression has been linked with tumorigenesis⁹ and metastasis¹⁰, although these studies are

only correlative. Peptides that mimic the cell adhesive region of fibronectin are, however, known to inhibit metastasis¹¹, which may indicate that tumour cells must interact with molecules such as fibronectin to metastasize. RhoC is a member of the Rho GTPase family that can regulate many cellular functions, most notably cytoskeletal organization, in response to extracellular factors¹². Enhanced expression of RhoC has been reported to correlate with the progression of pancreatic adenocarcinomas to a metastatic phenotype¹³. Thymosin β 4 is an actin-sequestering protein that regulates actin polymerization; its expression in renal tumours has been correlated with malignancy¹⁴. Expression of two other family members, thymosin β 10 and thymosin β 15, also correlates with metastasis^{4,15}. Other regulators of the cytoskeleton also appear on the list, including α -catenin and expressed sequence tags (ESTs) for α -actinin 1 and α -centractin. The altered expression of so many genes whose products regulate the actin cytoskeleton either directly or indirectly indicates that cytoskeletal organization may be important in tumour metastasis.

Also prominent on the list in Table 1 are several genes that encode extracellular matrix (ECM) proteins, as well as molecules that regulate their assembly. In addition to fibronectin, two collagen subunits, α 2(I) and α 1(III), the matrix Gla protein, fibromodulin and biglycan also are expressed at higher levels in the metastatic melanomas. Previous studies of matrix Gla protein have shown that it is overexpressed in breast carcinoma cell lines relative to normal breast epithelial cells¹⁶ and collagen expression has been correlated with the invasive potential of ocular melanomas¹⁰, but expression of the small interstitial proteoglycans biglycan and fibromodulin (which regulate collagen fibril formation^{17,18}) has yet to be linked to tumour progression. These findings support hypotheses that enhanced expression of ECM proteins may promote tumour cell survival or angiogenesis¹⁹.

Table 1 Enhanced gene expression in metastatic melanomas

Gene name	human A375						mouse B16					
	Human acc. number	Ch. no.	P	M1	M2	SM	Mouse acc. number	F0	F1	F2	F3	Nuc. ident.
Fibronectin	X02761	2	1	10.1	3.2	4.0	M18194	A	2.8	2.8	2.8	93%
RhoC	L25081	1	A	4.7	3.1	2.8	X80638	A	2.9	4.9	2.5	91%
Thymosin β 4	M17733	X	1	3.3	3.6	3.5	W41883	1	4.1	3.5	3.5	92%
t-PA	K03021	8	A	5.2	9.6	5.2	J03520	A	A	A	A	81%
Angiopoietin1	D13628	8	1	4.3	9.4	3.3	U83509					
IEX-1/Glu96	S81914	6	1	9.1	3.3	4.5	X67644	1	0.4	0.6	0.5	83%
RTP/NDR1	D87953	8	1	8.6	5.4	4.7	U60593	1	A	0.7	1.5	86%
Fibromodulin	U05291	1	A	8.3	4.7	8.2	X94998	1	2.0	2.0	1.1	80%
Hsp70	M11717	1	1	7.8	4.2	5.0	M20567	1	2.1	1.8	1.8	80%
IL13 Rec., α 2	U70981	X	1	7.6	2.9	3.1	U65747					
Sec61 β	L25085	9	1	3.8	4.7	3.3						
snRNP, poly. pep. C	HG1322-	9	1	3.8	5.3	3.2						
Collagen Ia2	Z74616	7	A	2.5	3.6	3.6	X58251	A	3.1	2.3	3.7	86%
UBE21	U45328	16	1	3.6	3.4	3.4						
KIAA0156	D63879	16	1	3.6	3.4	3.4						
TGF β superfamily	AB000584	19	1	3.4	3.4	3.0						
Surfactant protein C	J03890						M38314	A	32	12	16	
Lysozyme M							M21050	A	20	10	22	
Matrix Gla prot	X53331	12	1	3.2	4.4	1.1	D00613	1	12	11	5.4	81%
Tsa-1							U47737	A	9.7	6.1	7.2	
Collagen IIIa1	X06700	2	A	A	A	A	X52046	A	8.2	5.6	5.5	89%
Biglycan	J04599	X	A	A	3.7	A	L20276	A	3.8	4.4	6.9	87%
α -catenin	U03100	5	1.0	1.3	1.0	1.9	X59990	1	3.4	3.0	5.7	91%
Valosin-cont. prot.	AC004472						Z14044	1	3.0	3.9	5.9	
ERK-1	X60188	16	A	A	A	A	Z14249	1	2.6	2.6	3.0	85%
α -actinin 1							AA068062	1	3.6	3.3	7.3	
calmodulin							AA103356	A	4.8	6.7	5.5	
EIF4 γ							AA002277	A	4.7	3.2	2.6	
α -centractin							W48490	1	2.9	3.8	3.6	
IQGAP1							AA118739	A	3.6	3.5	3.2	
cathepsin s							W13263	A	2.8	2.8	3.1	
EF2							W90866	1	2.6	2.5	2.9	

Genes whose expression is consistently enhanced >2.5-fold in pulmonary metastases (M1, M2, SM, F1, F2 or F3) compared to poorly metastatic cells (P or F0) grown as subcutaneous tumours. The values for P and F0 are the average of two experiments performed with subcutaneous tumours from two mice injected with A375P or B16F0 cells. Data are presented as fold expression compared with the poorly metastatic tumours. When expression was below baseline, the expression was marked as absent (A) and was arbitrarily set at 20. Mouse expressed sequence tags (ESTs) are noted in italics and are named according to the gene to which they show the greatest sequence similarity. Ch. no., human chromosome where the gene resides. Nuc. ident., percentage of nucleotides identical between the human and mouse homologues, as determined by BLAST search. The accession number is the GenBank entry from which the oligonucleotide probe sequences were drawn.

* Mouse or human gene homologue exists in the UNIGENE database but was not part of the oligonucleotide probe set.

† No gene homologue was found in the UNIGENE database.




Figure 3 RhoC regulates melanoma cell chemotaxis and invasion. **a**, Poorly (P) or highly metastatic (M) A375 cells expressing rhoC, rhoA or dominant-negative (dn) rho were induced to migrate towards serum for 16 h. Over 25% of the plated A375M cells migrated within this time. Each bar represents the mean \pm s.e.m. of four experiments done in duplicate. **b**, The cell lines described above were induced to invade matrigel-coated membranes for 48 h. Over 30% of the plated A375M cells invaded within this time. Each bar represents the mean \pm s.e.m. of three experiments done in duplicate.

Several genes identified in other studies are conspicuous by their absence from our list. Metastasis suppressor genes, such as nm23, KiSS1 and CD82, can inhibit tumour metastasis². In our study all three of these genes were absent in both the parental A375 tumours and in the metastases (see Supplementary Information), indicating that, although expression of these genes may inhibit metastasis, lack of their expression is not sufficient for metastasis. Other genes not found in Table 1 but whose expression correlated with melanoma metastasis in previous studies include the Met tyrosine kinase receptor, matrix metalloproteinases (MMPs) such as MMP2, and the β 3-integrin subunit^{20–22}. In the B16 tumours, Met expression was higher in two of the three metastases but its expression was not detected in any of the A375 tumours, indicating that its expression may not be essential for these tumours to metastasize. Expression of MMP2 and of the β 3-integrin subunit was not significantly higher in any of the three metastases (see Supplementary Information), but their expression in both the parental and metastatic tumours may be sufficient to allow the tumour cells to metastasize.

Having uncovered 32 genes and ESTs whose expression patterns correlate with metastasis, we wished to investigate the function of one of these genes in this process. Because of its elevated expression in metastases derived from both tumour cell lines, RhoC was chosen to test the hypothesis that these expression studies identify genes essential for metastasis. The full-length human RhoC gene was cloned, subcloned into a retroviral vector and introduced into a retroviral packaging cell line. We used retroviral particles to infect the poorly metastatic A375P cells, and selected cells expressing high levels of RhoC by fluorescence-activated cell sorting (FACS). These cells, designated A375P-RhoC (expressing RhoC at 20 times the level expressed in A375M cells), were subjected to the experimental metastasis assay. As seen in Fig. 2c and Table 2, overexpression of RhoC markedly enhanced metastasis in this system.

Next we tested whether we could inhibit metastasis by expressing a known dominant-inhibitory Rho mutant (N19Rho)²³ in the highly metastatic A375M cells (a pool of M1, M2 and SM cells). This mutant is analogous to the N17Ras mutant that blocks Ras signalling²⁴. Ras dominant-negatives are actually antagonists of the guanine-nucleotide exchange factors (GNEFs) for Ras, rather than of Ras itself²³ and it is believed that dominant-negative RhoA antagonizes Rho GNEFs, thereby inhibiting RhoC. Expression of N19RhoA in the A375M cells markedly suppressed the generation of metastases when these cells were subjected to the experimental metastasis assay (Fig. 2d and Table 2), indicating that Rho activity may be necessary, and RhoC sufficient, for metastasis in these melanoma lines.




Figure 4 Metastatic capacity of A375 melanoma cells correlates with cell morphology. Poorly (a) or highly metastatic (c) A375 cells expressing rhoC (b) or dominant-negative rho (d) were plated on glass coverslips for 16 h at 37 °C, then fixed and stained with phalloidin to detect F-actin.

Having established a causal role for RhoC in metastasis, we set out to investigate how RhoC might regulate the ability of tumour cells to metastasize. Tumour cells must complete a complex series of steps to metastasize, one of the most basic of which is cell growth. Rho GTPases affect several aspects of growth control¹², so it was possible that RhoC might control tumour metastasis by regulating cell proliferation. We assayed the A375P, A375P-RhoC, A375M and A375M-dnRho cells for *in vitro* proliferation and *in vivo* tumorigenesis (see Supplementary Information). Proliferation in either assay was not significantly changed by altering RhoC expression or Rho activity, indicating that RhoC may regulate metastasis by a mechanism other than controlling cell proliferation.

Another function of Rho-family GTPases is to control cytoskeletal organization in response to extracellular factors¹². Cytoskeletal proteins are known effectors for events essential for cell motility²⁵. Therefore, RhoC may control metastasis by regulating cell motility. Metastatic A375M cells were more migratory (Fig. 3a) and more invasive (Fig. 3b) than the poorly metastatic A375P cells. Furthermore, RhoC could enhance the migratory and invasive capacity of the A375P cells, whereas dnRho inhibited motility and invasion of the A375M cells, indicating that RhoC may regulate metastasis by controlling cytoskeletal events essential for motility. We also observed that RhoC could induce in A375P cells an elongated morphology similar to that of A375M cells, while dnRho expression suppressed this morphology (Fig. 4). Another morphological difference noted in the A375M cells, the serum-induced formation of filopodia, also correlated with the metastatic capacity of these cells. However, filopodial protrusions (which are regulated by the Rho subfamily member Cdc42 (ref. 12) were not altered by expression of RhoC or dnRho (data not shown), indicating that regulation of these actin-based structures may occur upstream (or independently) of Rho.

We have identified RhoC as essential for tumour metastasis. Compared with RhoA, the canonical family member, little is

Table 2 Pulmonary metastases

Cell line	No. of metastases	No. of mice
A375P	0,0,0,0,1,5,10	8
A375P-RhoC	56,70,>100,>100	4
A375M	all >100	8
A375M-dnRho	13,24,29,32	4

Numbers of pulmonary metastases identified on the surface of the lungs of mice injected with A375P, A375P-RhoC, A375M or A375M-dnRho cells.

known about RhoC. RhoA and RhoC are highly homologous, with only six non-conservative amino-acid substitutions, all in the carboxy-terminal end of the molecules. It might be thought that RhoA should be able to enhance tumour metastasis. However, RhoA is expressed at equivalent levels in both the poorly and highly metastatic tumours (see Supplementary Information), indicating that the level of RhoA expression in the A375 cells is not sufficient for metastasis. Furthermore, when expressed at equivalent levels, RhoC was a better motogen than was RhoA (Fig. 3). These results indicate that there may be a functional difference between Rho subfamily members that requires further investigation. Finally, the observation that expression of a single gene is sufficient to induce metastasis is perhaps surprising, given that metastasis is such a complex process. We suspect, however, that many cells within the heterogeneous tumorigenic A375P population may be genetically primed for metastasis so that introduction of a single gene (such as RhoC) which affects a process essential for metastasis is sufficient for metastasis. We are currently examining whether RhoC is capable of inducing metastasis in other tumorigenic cells. □

Methods

Cell lines

The A375 (ATCC#CRL-1619) and B16 (ATCC#CRL-6322) cell lines were maintained as described⁷. Cells were harvested by trypsinization, washed in PBS and diluted to 2.5×10^6 cells per ml for A375 cells and 2.5×10^5 cells per ml for B16 cells.

Experimental metastasis assay

A375 cells were injected either intravenously (0.2 ml) into the lateral tail vein or subcutaneously (0.1 ml) into the dorsal flank of nude mice, and B16 cells were injected into syngeneic C57BL/6 mice. Three (for B16) to eight (for A375) weeks after injection the mice were killed; the lungs were removed and washed and the pulmonary metastases on the lung surface were counted under a dissecting microscope. Metastatic nodules were removed aseptically, minced and grown *in vitro*, or snap-frozen in liquid nitrogen to purify RNA.

Tumours and tumour-derived cell lines

A375M1, M2 and SM lines were selected using the experimental metastasis assay for their enhanced ability to form experimental pulmonary metastases⁶. Line M1 was derived from metastases isolated from mice injected intravenously with the A375P cells, line M2 from mice injected with A375M1 cells, and line SM was a gift from I. Fidler and was derived by an identical selection procedure⁷. B16 lines were derived in an identical manner, with F1 cells derived from B16F0 cells, F2 from B16F1 cells and F3 from B16F2 cells. The A375M cell line is a pool of cells from A375M1, M2 and SM cells. A375P and A375M cells used in retroviral gene transfer studies were transfected with a plasmid containing the ecotropic receptor (a gift from H. Lodish) and selected for neomycin-resistance. Mock-infected or uninfected cells were used as negative controls in the metastasis assays.

Array hybridization

Total RNA was prepared with a Qiagen RNeasy mini-kit according to the manufacturer's instructions. We prepared cRNA for hybridization essentially as described²⁸. Oligonucleotide arrays (GeneChip, Affymetrix) composed of 7,070 human (HUM 6.8K) or 6,347 mouse (MUR 6K) genes and ESTs were used for hybridization according to the manufacturer's instructions. Arrays were scanned using an Affymetrix confocal scanner and analysed using GeneChip 3.0 software (Affymetrix). Intensity values were scaled so that the overall fluorescence intensity of each chip of the same type was equivalent. For a gene to be selected as induced, it has to be expressed in all three metastatic samples at least 2.5 times higher than in the poorly metastatic sample, with experiments done in duplicate. Where expression in the poorly metastatic sample was below baseline (set at 20, the point below which changes in expression could be determined with high confidence), it was determined to be absent and was set to 20.

Retroviral gene transfer

An EcoRI fragment of pCR-BluntII-RhoC containing the entire coding region of human RhoC (see Supplementary Information) was inserted into the EcoRI site of the retroviral bicistronic expression vector pMX-IRES-GFP (pMIG; ref. 27) containing enhanced green fluorescent protein (GFP) as an expression marker. An EcoRI fragment of pEXV-RhoA or pEXV-N19RhoA (a dominant-negative Rho mutant, dnRho) was inserted into the EcoRI site of pMIG. We transfected pMIG-RhoC, pMIG-RhoA and pMIG-dnRho into 293T cell-derived retroviral producer lines (Phoenix cells) as described (see www.stanford.edu/group/nolan/) and A375P or M cells were infected. Cells were sorted by FACStar (Becton-Dickinson) according to their GFP levels. RNase protection assays showed that RhoC was expressed at 5- to 50-fold higher levels than in the A375M cells, whereas RhoC and RhoA were expressed at similar levels in the A375P-RhoC and A375P-RhoA cells (as determined by GFP expression).

Chemotaxis and invasion assays

Cell migration and invasion assays were performed using 8.0- μ m pore size Transwell inserts (Costar Corporation) or Biocoat Matrigel invasion chambers (Becton-Dickinson), respectively²⁹. Each data point represents the average of 3 or 4 individual experiments, done in duplicate, and error bars represent the standard error of the mean.

Immunofluorescence

Adherent cells were fixed, permeabilized and stained as described²⁹.

Received 31 January; accepted 15 May 2000.

1. Van Noorden, C. J. F., Meade-Tollin, L. C. & Bosman, F. T. Metastasis. *Am. Sci.* **86**, 130–141 (1998).
2. Fidler, I. J. & Radinsky, R. Search for genes that suppress cancer metastasis. *J. Natl Cancer Inst.* **88**, 1700–1703 (1996).
3. Roberts, D. D. Regulation of tumor growth and metastasis by thrombospondin-1. *FASEB J.* **10**, 1183–1191 (1996).
4. Bao, L. *et al.* Thymosin β 15: a novel regulator of tumor cell motility upregulated in metastatic prostate cancer. *Nature Med.* **2**, 1322–1328 (1996).
5. Habets, G. G. M. *et al.* Identification of an invasion-inducing gene, *Tiam-1*, that encodes a protein with homology to GDP-GTP exchangers for rho-like proteins. *Cell* **77**, 537–549 (1994).
6. Fidler, I. J. Selection of successive tumour lines for metastasis. *Nature* **242**, 148–149 (1973).
7. Kozlowski, J. M., Hart, I. R., Fidler, I. J. & Hanna, N. A human melanoma cell line heterogeneous with respect to metastatic capacity in athymic nude mice. *J. Natl Cancer Inst.* **72**, 913–917 (1984).
8. Welch, D. R. *et al.* Microcell-mediated transfer of chromosome 6 into metastatic human C8161 melanoma cells suppresses metastasis but does not inhibit tumorigenicity. *Oncogene* **9**, 255–262 (1994).
9. Zhang, L. *et al.* Gene expression profiles in normal and cancer cells. *Science* **276**, 1268–1272 (1997).
10. Maniotis, A. J. *et al.* Vascular channel formation by human melanoma cells *in vivo* and *in vitro*: vasculogenic mimicry. *Am. J. Pathol.* **155**, 739–752 (1999).
11. Humphries, M. J., Olden, K. & Yamada, K. M. A synthetic peptide from fibronectin inhibits experimental metastasis of murine melanoma cells. *Science* **233**, 467–469 (1986).
12. Van Aels, L. & D'Souza-Schorey, C. Rho GTPases and signaling networks. *Genes Dev.* **11**, 2295–2322 (1997).
13. Suwa, H. *et al.* Overexpression of the rhoC gene correlates with progression of ductal adenocarcinoma of the pancreas. *Br. J. Cancer* **77**, 147–152 (1998).
14. Hall, A. K. Differential expression of thymosin genes in human tumors and in the developing human kidney. *Int. J. Cancer* **48**, 672–677 (1991).
15. Weterman, M. A. J., van Muijen, G. N. P., Ruiter, D. J. & Bloemers, H. P. J. Thymosin β -10 expression in melanoma cell lines and melanocytic lesions: a new progression marker for human cutaneous melanoma. *Int. J. Cancer* **53**, 278–284 (1993).
16. Chen, L., O'Bryan, J. P., Smith, H. S. & Liu, E. Overexpression of matrix Gla protein mRNA in malignant human breast cells: isolation by differential cDNA hybridization. *Oncogene* **5**, 1391–1395 (1990).
17. Schonherr, E. *et al.* Interaction of biglycan with type 1 collagen. *J. Biol. Chem.* **270**, 2776–2783 (1995).
18. Svensson, L. *et al.* Fibromodulin-null mice have abnormal collagen fibrils, tissue organization, and altered lumican deposition in tendon. *J. Biol. Chem.* **274**, 9636–9647 (1999).
19. Ruoslahti, E. Fibronectin and its integrin receptors in cancer. *Adv. Cancer Res.* **76**, 1–20 (1999).
20. Jeffers, M., Rong, S. & Vande Woude, G. F. Enhanced tumorigenicity and invasion-metastasis by hepatocyte growth factor/scatter factor-Met signalling human cells concomitant with induction of the urokinase proteolysis network. *Mol. Cell. Biol.* **16**, 1115–1125 (1996).
21. Chambers, A. F. & Matrisian, L. M. Changing views of the role of matrix metalloproteinases in metastasis. *J. Natl Cancer Inst.* **89**, 1260–1270 (1997).
22. Albelda, S. M. *et al.* Integrin distribution in malignant melanoma: association of the β 3 subunit with tumor progression. *Cancer Res.* **50**, 6757–6764 (1990).
23. Quilliam, L. A., Khosravi-Par, R., Huff, S. Y. & Der, C. J. Guanine nucleotide exchange factors: activators of the Ras superfamily of proteins. *BioEssays* **17**, 395–404 (1995).
24. Feig, L. A. & Cooper, G. M. Inhibition of NIH 3T3 cell proliferation by a mutant ras protein with preferential affinity for GDP. *Mol. Cell. Biol.* **8**, 3235–3243 (1988).
25. Lauffenburger, D. A. & Horowitz, A. F. Cell migration: a physically integrated molecular process. *Cell* **84**, 359–369 (1996).
26. Fambrough, D., McClure, K., Kazlauskas, A. & Lander, E. S. Diverse signaling pathways activated by growth factor receptors induce broadly overlapping, rather than independent, sets of genes. *Cell* **97**, 727–741 (1999).
27. Liu, X. *et al.* Transforming growth factor β -induced phosphorylation of Smad3 is required for growth inhibition and transcriptional induction in epithelial cells. *Proc. Natl Acad. Sci. USA* **94**, 10669–10674 (1997).
28. Yebra, M. *et al.* Requirement of receptor-bound urokinase-type plasminogen activator for integrin α β 5-directed cell migration. *J. Biol. Chem.* **271**, 29393–29399 (1996).
29. Clark, E. A., King, W. G., Symons, M. & Hynes, R. O. Integrin-mediated signals regulated by members of the rho family of GTPases. *J. Cell Biol.* **142**, 573–586 (1998).

Supplementary information is available on Nature's World-Wide Web site (<http://www.nature.com>) or as paper copy from the London editorial office of Nature.

Acknowledgements

We thank C. Huard, C. Whittaker, S. Robinson, J. Lively, D. Hirsch, D. Crowley and P. Tamayo for technical assistance and advice, and H. Lodish, G. Nolan and J. Fidler, for reagents. This work was supported in part by grants from the National Cancer Institute (to R.O.H.), Affymetrix, Inc., Bristol-Myers Squibb and Millenium Pharmaceuticals (to E.S.L.), and a Merck/MIT postdoctoral fellowship (to E.A.C.). R.O.H. is an investigator and E.A.C. was an associate of the Howard Hughes Medical Institute.

Correspondence and requests for materials should be addressed to R.O.H. (e-mail: rohynes@mit.edu).